Oncologists Offer Ideas To Ease Cancer’s Costs

Oncologists Offer Ideas To Ease Cancer's Costs New drugs routinely priced at $100,000 a year, ASCO says By Robert Preidt | HealthDay Reporter | WebMD | See Original Article Here WEDNESDAY, July 19, 2017 (HealthDay News) -- New cancer drugs routinely cost $100,000 a year or more, and older cancer drugs are rising in price, too. Now, the American Society…
Continue Reading »

Making cancer vulnerable to immune attack

Making cancer vulnerable to immune attack CRISPR-Cas9 is revealing new drug targets that could boost cancer immunotherapy July 19, 2017 |Harvard Gazette | By Kat J. McAlpine, Dana-Farber/Boston Children’s Communications | See Original Article Here Credit: Haining Lab, Dana-Farber/Boston Children's - Genetic screening for cancer immunotherapy targets cancer cells (colored shapes), each with a different…
Continue Reading »

Grass-roots Funding for E-RMS Research

There is a once-in-a-lifetime(!) opportunity for ERMS research: <; Children's Cancer Therapy Development Institute (cc-TDI) is in a unique position to raise half a million dollars specifically to develop new treatments for embryonal rhabdomyosarcoma. A donor is making a 1:1 match and will give up to $250,000 so if we reach our goal, cc-TDI could…
Continue Reading »

Should young patients with rare sarcoma subtypes be included in adult sarcoma trials?

Should young patients with rare sarcoma subtypes be included in adult sarcoma trials? HemOnc Today |  July 10, 2017 | Ian Judson | See Original Article Here Click here to read the Cover Story, “Deeper understanding of disease biology may expand sarcoma treatment options.” Yes. It is nonsense that clinical trials continue to be performed in diseases like soft…
Continue Reading »

Custom cancer vaccines safely fight and kill tumors in early human trials

Custom cancer vaccines safely fight and kill tumors in early human trials It’s early and there are many hurdles, but data so far suggests safety, efficacy. BETH MOLE - 7/6/2017, 4:06 PM | ars Technica | See Original Here Melanoma Cells With swift shots to the arm, doctors safely and effectively prime our immune systems to fight off…
Continue Reading »

Combining immunotherapies effective against mouse model of cancer

Combining immunotherapies effective against mouse model of cancer Recent study results suggest that combining virotherapy and PD-1 blockades may be more effective than either approach alone Date: June 19, 2017 | Source: Nationwide Children's Hospital | See Original Here Summary: A recent study points to a new treatment strategy for rhabdomyosarcoma that takes advantage of…
Continue Reading »

At big cancer meeting, a big question: Is the U.S. ‘losing its edge’?

At big cancer meeting, a big question: Is the ‘losing its edge’? By LIZ SZABO — KAISER HEALTH NEWS | JUNE 2, 2017 | See Original Here Less and less of the research presented at a prominent cancer conference is supported by the National Institutes of Health, a development that some of the country’s top scientists…
Continue Reading »

Children who survive cancer face fewer serious long-term health issues – study

Children who survive cancer face fewer serious long-term health issues – study Report covering children diagnosed from 1970 to 1999 finds rate of severe long-term side effects dropped from to Jessica Glenza in Chicago, Illinois | The Guardian | Friday 2 June 2017  EDT | See Original Here The most dramatic drops in long-term health complications found…
Continue Reading »

TLC178 designated by US FDA as drug for rare paediatric disease in the treatment of Rhabdomyosarcoma

TLC178 designated by US FDA as drug for rare paediatric disease in the treatment of Rhabdomyosarcoma By Laxmi Iyer - April 26, 2017 | | See Original Here Taiwan Liposome Company, Ltd.,(TLC) (4152:TT) today announced that its oncology drug candidate TLC178 has been designated as a drug for a rare pediatric disease in the treatment of rhabdomyosarcoma…
Continue Reading »

Cancer Math and Rhabdomyosarcoma: Crowdfunding Request

Cancer Math and Rhabdomyosarcoma: Using engineering principles to develop personalized therapies for patients with rhabdomyosarcoma Last year Dr. Noah Berlow, a Postdoctoral Fellow at the Children's Cancer Therapy Development Institute (c-TDI) presented a webinar on the work he is doing in cancer math. With the reductions in federal research funding - and much greater cuts…
Continue Reading »
Skip to toolbar